


Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.



## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(Use as many sheets as necessary)*

**Complete if Known**


<b>Application Number</b>	10/698,073
<b>Filing Date</b>	October 29, 2003
<b>First Named Inventor</b>	Cynthia B. Robinson
<b>Art Unit</b>	1617
<b>Examiner Name</b>	San Ming R. Hui
<b>Attorney Docket Number</b>	30775-723.201

Sheet	1	of	1
-------	---	----	---

[illegible][illegible]

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.**



PTO SB 05A (08-03)

Approved for use through 07 31 2009. OMB C551-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/698,073
				Filing Date	October 29, 2003
				First Named Inventor	Cynthia B. Robinson
				Art Unit	1624
				Examiner Name	Unassigned
Sheet	1	of	1	Attorney Docket Number	30775-723-201


**U.S. PATENT DOCUMENTS**


Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	1	US- 6,087,351	07-11-2000	Jonathan W. Nyce	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	2	Milgrom, H., et al., "Treatment of Childhood Asthma with Anti-Immunoglobulin E Antibody (Omalizumab)", <i>Pediatrics</i> (2001) 108(28): 1-10.	

Examiner Signature		Date Considered	8/5/2007
--------------------	---	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

PTO FORM 1449

ATTY. DOCKET NO.

02486.0078.NPUS01

APPLICATION NO.

10/698,073

APPLICANT


Cynthia B. Robinson, et al.

FILING DATE

October 29, 2003

GROUP

Not yet Assigned



## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>ll</i>	1.	4,393,066	Jul. 1983	Garrett et al.			
	2.	4,499,064	Feb. 1985	Shive			
	3.	4,575,498	Mar. 1986	Holmes et al.			
	4.	4,628,052	Dec. 1986	Peat			
	5.	4,920,115	Apr. 1990	Nestler et al.			
	6.	4,931,441	Jun. 1990	Lawrence			
	7.	4,985,443	Jan. 1991	Montes			
	8.	5,021,417	Jun. 1991	Prost			
	9.	5,059,595	Oct. 1991	Le Grazie			
	10.	5,077,284	Dec. 1991	Loria et al.			
	11.	5,110,810	May 1992	Eich et al.			
	12.	5,118,505	Jun. 1992	Költringer			
	13.	5,162,198	Nov. 1992	Eich et al.			
	14.	5,173,488	Dec. 1992	Haeger			
	15.	5,177,076	Jan. 1993	Nijkerk et al.			
	16.	5,266,312	Nov. 1993	Leung et al.			
	17.	5,270,305	Dec. 1993	Palmer			
	18.	5,347,005	Sep. 1994	Mueller et al.			
	19.	5,407,684	Apr. 1995	Loria et al.			
	20.	5,407,927	Apr. 1995	Morales et al.			
	21.	5,422,258	Jun. 1995	Chang			
	22.	5,489,581	Feb. 1996	Daynes et al.			
	23.	5,527,789	Jun. 1996	Nyce			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<p align="center"><b>LIST OF REFERENCES CITED BY APPLICANT</b>  <i>(Use several sheets if necessary)</i></p> <p align="center"><b>PTO FORM 1449</b></p>	<p>ATTY. DOCKET NO.  <b>02486.0078.NPUS01</b></p>	<p>APPLICATION NO.  <b>10/698,073</b></p>
	<p>APPLICANT  <b>Cynthia B. Robinson, et al.</b></p>	
	<p>FILING DATE  <b>October 29, 2003</b></p>	<p>GROUP  <b>Not yet Assigned</b></p>

u	24.	5,532,230	Jul. 1996	Daynes et al.				
	25.	5,538,734	Jul. 1996	Le Grazie				
	26.	5,543,144	Aug. 1996	Chang				
	27.	5,583,126	Dec. 1996	Daynes et al.				
	28.	5,610,140	Mar. 1997	Goodfellow et al.				
	29.	5,635,496	Jun. 1997	Daynes et al.				
	30.	5,653,980	Aug. 1997	Hellman				
	31.	5,660,835	Aug. 1997	Nyce				
	32.	5,686,438	Nov. 1997	Daynes et al.				
	33.	5,703,063	Dec. 1997	Chasalow, et al.				
	34.	5,767,278	Jun. 1998	Gaeta et al.				
	35.	5,811,418	Sep. 1998	Daynes et al.				
	36.	5,859,000	Jan. 1999	Dowell et al.				
	37.	5,861,391	Jan. 1999	Yen et al.				
	38.	5,945,294	Aug. 1999	Frank et al.				
	39.	5,948,434	Sep. 1999	Labrie				
	40.	5,965,709	Oct. 1999	Presta et al.				
	41.	5,994,511	Nov. 1999	Lowman et al.				
	42.	6,087,351	Jul. 2000	Nyce				
	43.	6,093,706	Jul. 2000	Zeligs				
	44.	2002/0042401	Apr. 2002	Ferguson et al.				
	45.	2003/0013772	Jan. 2003	Murphy et al.				
	46.	2003/0138434	Jul. 2003	Campbell et al.				
	47.	2003/0139331	Jul. 2003	Martin et al.				

*W. F. Chene*

7/5/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>LIST OF REFERENCES CITED BY APPLICANT</b> <i>(Use several sheets if necessary)</i> <b>PTO FORM 1449</b>	ATTY. DOCKET NO.	APPLICATION NO.
	02486.0078.NPUS01	10/698,073
	APPLICANT Cynthia B. Robinson, et al.	
	FILING DATE	GROUP
	October 29, 2003	Not yet Assigned

FOREIGN PATENT DOCUMENTS								
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	48. <input checked="" type="checkbox"/>	WO 93/16704		PCT				
	49. <input checked="" type="checkbox"/>	WO 96/16680		PCT				
	50. <input checked="" type="checkbox"/>	WO 97/48367		PCT				
	51. <input checked="" type="checkbox"/>	WO 98/03180		PCT				
	52. <input checked="" type="checkbox"/>	WO 00/54763		PCT				
	53. <input checked="" type="checkbox"/>	WO 01/015745		PCT				
	54. <input checked="" type="checkbox"/>	WO 02/069955		PCT				
	55. <input checked="" type="checkbox"/>	WO 02/85296		PCT				
	56. <input checked="" type="checkbox"/>	WO 03/072572		PCT				
	57. <input checked="" type="checkbox"/>	WO 04/014993 A2		PCT				
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)								
	58. <input checked="" type="checkbox"/>	Araneo et al., "Dehydroepiandrosterone Reduces Progressive Dermal Ischemia Caused by Thermal Injury", <i>J. Surg. Res.</i> 59(2):250-62 (1995).						
	59. <input checked="" type="checkbox"/>	Bonnett et al., "Dehydroepiandrosterone (DHEA) prevents and reverses chronic hypoxic pulmonary hypertension," <i>PNAS</i> 100(16):9488-93 (2003).						
	60. <input checked="" type="checkbox"/>	Budavari, The Merck Index 11 <sup>th</sup> ed., 1989, pp. 660-661, monograph 4141.						
	61. <input checked="" type="checkbox"/>	Coleridge et al., "Intravenous aminophylline confers no benefit in acute asthma treated with intravenous steroids and inhaled bronchodilators", <i>Aust. N.Z. J. Med.</i> 23:348-54 (1993).						
	62. <input checked="" type="checkbox"/>	Dashtaki et al., "Dehydroepiandrosterone and Analogs Inhibit DNA Binding of AP-1 and Airway Smooth Muscle Proliferation <sup>1</sup> ," <i>J. Pharmacol. Exp. Thera.</i> 285(2):876-83 (1998).						
	63. <input checked="" type="checkbox"/>	Dompeling et al., "Treatment with Inhaled Steroids in Asthma and Chronic Bronchitis: Long Term Compliance and Inhaler Technique", <i>Family Practice</i> 9(2):161-6 (1992).						
	64. <input checked="" type="checkbox"/>	Dunn et al., "Dehydroepiandrosterone sulphate concentrations in asthmatic patients: pilot study," <i>N.Z. J. Med.</i> 97(768):805-8 (1984).						
	65. <input checked="" type="checkbox"/>	Duplantier et al., Novel pharmacological approaches to the treatment of asthma: status and potential of therapeutic classes", <i>DDT</i> 1(5):199-207 (1996).						

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

NO Received DOC X

<b>LIST OF REFERENCES CITED BY APPLICANT</b> <i>(Use several sheets if necessary)</i>  <b>PTO FORM 1449</b>	ATTY. DOCKET NO. <b>02486.0078.NPUS01</b>	APPLICATION NO. <b>10/698,073</b>
	APPLICANT <b>Cynthia B. Robinson, et al.</b>	
	FILING DATE <b>October 29, 2003</b>	GROUP <b>Not yet Assigned</b>

66.	X	Dworski <i>et al.</i> , "Conspectus: Inhaled Steroids in Asthma", <i>Comprehensive Therapy</i> , 18:3 (1992).
67.	X	Fehér <i>et al.</i> , "Adrenocortical Function in Bronchial Asthma", <i>Acta Medica Hungarica</i> 40(2-3):125-32 (1983).
68.	X	Fehér <i>et al.</i> , "Dehydroepiandrosterone Therapy of Patients with Corticosteroid Dependent Bronchial Asthma," <i>Natl. Institute of Rheumatism and Physiotherapy, in XIII Congress of the European Academy of Allergology and Clinical Immunology</i> , eds. (Saba, <i>et al.</i> , Debrecen Hungary (1986).
69.	X	Hampel <i>et al.</i> , "Dehydroepiandrosterone sulphate reduces chronic hypoxic pulmonary hypertension in rats," <i>J. Eur. Respir.</i> 21:862-5 (2003).
70.	X	Holzmann <i>et al.</i> , "Therapy of Psoriasis with Dehydroepiandrosterone-Enanthate. II. Intramuscular Depot Application of 300 mg", <i>Arch. Dermatol. Forsch.</i> 247(1):23-8 (1973) (German with English Abstract).
71.	X	Hummel <i>et al.</i> , "Comparison of oral-steroid sparing by high-dose and low-dose inhaled steroid in maintenance treatment of severe asthma", <i>The Lancet</i> , 340(8834/8835):1483-7 (1992).
72.	X	Itagaki <i>et al.</i> , "Effect of Cortisol on the Release of Human Decidual", <i>Caplus</i> , 114875 (1991) (Japanese with English Abstract).
73.	X	Koó <i>et al.</i> , "Our experiences with Dehydroepiandrosterone Therapy in Steroid-Dependent Intrinsic Bronchial Asthma", <i>Orvosi Hetilap</i> 128(38):1995-7 (1987) (Hungarian).
74.	X	Koó <i>et al.</i> , "Our experiences with Dehydroepiandrosterone Therapy in Steroid-Dependent Intrinsic Bronchial Asthma", <i>Orvosi Hetilap</i> 128(38):1995-7 (1987) (English translation).
75.	X	Lejeune, "Pathogenesis of Mental Impairment in Trisomy 21", <i>Annales de Génétique</i> , 92:27643 (1996) (French with English Abstract).
76.	X	Mileva <i>et al.</i> , "Androstenedione, DHEA sulfate, cortisol, aldosterone and testosterone in bronchial asthma patients", 07608054 (1990) (Russian with English Abstract).
77.	X	Nakagawa, <i>et al.</i> , "The Properties of Water of Crystallization of Sodium Prasterone Sulfate," <i>Chem. Pharm. Bull</i> 29(5):1466-9 (1981)
78.	X	Nakagawa <i>et al.</i> , "The Grinding and Drying on the Solid State Stability of Sodium Prasterone Sulfate," <i>Chem. Pharm. Bull</i> 30(1):242-8 (1982)
79.	X	Pashko <i>et al.</i> , "Inhibition of 7,12-dimethylbenz(a)anthracene-induced Skin Papillomas and Carcinomas by Dehydroepiandrosterone and 3-beta-methylandro-5-en-17-one in mice", <i>Cancer Res.</i> 45(1):164-6 (1985).
80.	X	Peeters <i>et al.</i> , "Differences in Purine Metabolism in Patients with Down's Syndrome", <i>J. Intellect. Diabil. Res.</i> 37:471 (1993). Abstract.

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Not Considered*

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary) <b>PTO FORM 1449</b>	ATTY. DOCKET NO.	APPLICATION NO.
	02486.0078.NPUS01	10/698,073
	APPLICANT	
	Cynthia B. Robinson, et al.	
	FILING DATE	GROUP
	October 29, 2003	Not yet Assigned

81.	<input checked="" type="checkbox"/>	Presta <i>et al.</i> , "Humanization of an antibody directed against IgE", <i>J. Immunol.</i> 151(5):2623-32 (1993) (abstract only)
82.	<input checked="" type="checkbox"/>	Reed, "Aerosol Steroids as Primary Treatment of Mild Asthma", <i>New England J. Med.</i> , 325(6):425-6 (1991).
83.	<input checked="" type="checkbox"/>	Rowe <i>et al.</i> , "Effectiveness of Steroid Therapy in Acute Exacerbations of Asthma: A Meta-analysis", <i>Amer. J. Emergency Med.</i> , 10(4):301-10 (1992).
84.	<input checked="" type="checkbox"/>	Saini <i>et al.</i> , "Down-Regulation of Human Basophil IgE and FC $\epsilon$ RI $\alpha$ Surface Densities and Mediator Release by Anti-IgE-Infusions Is Reversible in Vitro and In Vivo", <i>J. Immunol.</i> 162:5624-30 (1999)
85.	<input checked="" type="checkbox"/>	Sasaki <i>et al.</i> , "Cervical Ripening with Dehydroepiandrosterone Sulphate", <i>Br. J. Obstet. Gynaecol.</i> 89(3):195-8, (1982).
86.	<input checked="" type="checkbox"/>	Schulman, "Development of a Monoclonal Anti-Immunoglobulin E Antibody (Omalizumab) for the Treatment of Allergic Respiratory Disorders", <i>Am. J. Respir. Crit. Care Med.</i> 164:S6-11 (2001)
87.	<input checked="" type="checkbox"/>	Sciarra <i>et al.</i> , "Aerosols", Remington's Pharmaceutical Sciences, 18 <sup>th</sup> ed. (1990), Eds. Gennaro <i>et al.</i> , pp. 1873-5 and 1694-1712.
88.	<input checked="" type="checkbox"/>	Sharma <i>et al.</i> , "Screening of potential chemopreventive agents using biochemical markers of carcinogenesis", <i>Cancer Res.</i> 54(22):5848-55 (1994).
89.	<input checked="" type="checkbox"/>	Shomali, "The Use of Anti-Aging Hormones. Melatonin. Growth Hormone, Testosterone, and Dehydroepiandrosterone: Consumer Enthusiasm for Unproven Therapies", <i>Md. Med. J.</i> 46(4):181-6 (1997).
90.	<input checked="" type="checkbox"/>	Sonka <i>et al.</i> , "Gout and Dehydroepiandrosterone: 3. DHEA Administration", <i>Endokrynologia Polska</i> 24(3):209-18 (1973).
91.	<input checked="" type="checkbox"/>	Sur <i>et al.</i> , "Double-blind trial pyroxidine (vitamin B6) in the treatment of steroid-dependent asthma", <i>Ann. Allergy</i> , 70:147-52 (1993).
92.	<input checked="" type="checkbox"/>	Schwartz <i>et al.</i> , "Inhibition of 7,12-dimethylbenz[a]anthracene- and urethan-induced lung tumor formation in A/J mice by long-term treatment with dehydroepiandrosterone," <i>Carcinogenesis</i> 2(12):1335-7 (1981)
93.	<input checked="" type="checkbox"/>	Van de Graaf <i>et al.</i> , "Respiratory Membrane Permeability and Bronchial Hyperreactivity in Patients with Stable Asthma: Effects of Therapy with Inhaled Steroids", <i>Bronchial Asthma and Respiratory Membrane Permeability</i> 143:362-8 (1991).
94.	<input checked="" type="checkbox"/>	Van Vollenhoven <i>et al.</i> , "Dehydroepiandrosterone in SLE. Results of a Double-Blind, Placebo-Controlled, Randomized Clinical Trial.", <i>Arthritis Rheum.</i> 38(12): 1826-31 (1995).
95.	<input checked="" type="checkbox"/>	Wolkowitz <i>et al.</i> , "Dehydroepiandrosterone Treatment of Depression", <i>Biol. Psychiatry</i> 41(3):311-8. (1997).

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Not considered - does not provide by applicant.